A Pan-Cancer View of the Immune Landscape in the Tumor Microenvironment via RNA and their Potential for Biomarkers in Clinical Trials

Immune-based biomarkers for measurement of tumor microenviornment (TME)

Author: Wendell Jones

Immune-based biomarkers are now commonly available when measuring the tumor microenvironment (TME), although many are based on immuno-histochemistry methods which sometimes have drawbacks: specificity, quantitation, variety. In addition, next-gen RNA sequencing and focused RNA assays are now much more accessible (for example, processing formalin-fixated material has a much higher degree of success) and are commonly employed in clinical trials to measure tumor activity and immune cell content in the TME. Download our poster from SITC 2018 to learn about our gene signatures for immune activity.

Complete the form below to access this scientific poster